FREE MEMBERSHIP Includes » ABL Advisor eNews + iData Blasts | JOIN NOW ABLAdvisor Gray ABLAdvisor Blue
Skip Navigation LinksHome / News / Read News


Oxford Finance Inks $10MM Secured Term Loan with Inhibrx

August 26, 2020, 09:00 AM
Filed Under: Life Sciences

Oxford Finance LLC, a specialty finance firm that provides senior debt to life sciences and healthcare services companies worldwide, announced that it closed a $10 million senior secured term loan with Inhibrx, Inc., a clinical-stage biotechnology company focused on developing a broad pipeline of novel biologic therapeutic candidates.The funds, which were secured prior to the Company's recent initial public offering, will provide general growth capital as Inhibrx aims to evolve into a commercial-stage biotechnology company.

Inhibrx combines a deep understanding of target biology with innovative protein engineering, proprietary discovery technologies, and an integrative approach to research and development to design highly differentiated therapeutic candidates. The Company has a pipeline of four programs in Phase 1 clinical trials targeting cancer and respiratory diseases.

"This closing represents Oxford's second opportunity with Inhibrx," said Christopher A. Herr, senior managing director at Oxford. "The Company is steadily advancing in its clinical pipeline, with its broad-based suite of platform technologies the Company can generate antibodies across several therapeutic areas, including oncology and respiratory illnesses. We are thrilled to continue supporting their promising growth and development."

Comments From Our Members

You must be an ABL Advisor member to post comments. Login or Join Now.